The US Food and Drug Administration has issued an approval letter for the new features and intended uses of the Planmed Verity orthopedic imaging solution. According to the company, the improved Verity now offers enhanced image quality, new options for head and neck imaging, the Planmeca Ultra Low Dose imaging protocol for lower patient doses, and the Planmeca CALM algorithm for motion artifact correction.
“We are excited to release the improved, XR-29 compliant Planmed Verity with its new dental and ENT imaging options. These features are something our customers have requested, and we are happy to answer their needs,” said Johan Moed, national sales manager of Planmed USA. “This unit is now more versatile than ever before. It is an easy to use and cost effective solution, which makes it a great tool for any imaging center, clinic, or hospital.”
By reducing artifacts caused by patient movement, Planmeca CALM is especially useful in challenging weight-bearing examinations in which patients have a tendency to move, the company reports. Also, the Planmeca Ultra Low Dose imaging protocol further reduces Verity’s already low and effective patient doses, Planmed says, without compromising diagnostic image quality.
“The work done on the iterative algorithms further strengthens our commitment to offering high-quality imaging solutions with extremely low patient radiation doses. We are delighted to start delivering scanners with these exciting features to our customers in the United States,” Moed said.
Related Articles
Imaging System Offers Multiple Modalities
Algorithm Compensates for Patient Movement in 3-D Scanning
Planmeca Chooses Partners for CAD/CAM Portfolio Distribution
